Compare · HKPD vs MCK
HKPD vs MCK
Side-by-side comparison of Cellyan Biotechnology Co. Ltd (HKPD) and McKesson Corporation (MCK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HKPD and MCK operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- MCK is the larger of the two at $92.15B, about 8019.3x HKPD ($11.5M).
- Over the past year, HKPD is down 77.7% and MCK is up 8.3% - MCK leads by 86.0 points.
- MCK has been more active in the news (35 items in the past 4 weeks vs 4 for HKPD).
- MCK has more recent analyst coverage (25 ratings vs 0 for HKPD).
- Company
- Cellyan Biotechnology Co. Ltd
- McKesson Corporation
- Price
- $0.48-5.73%
- $766.63-1.18%
- Market cap
- $11.5M
- $92.15B
- 1M return
- -21.31%
- +1.61%
- 1Y return
- -77.67%
- +8.34%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 4
- 35
- Recent ratings
- 0
- 25
McKesson Corporation
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Latest HKPD
- SEC Form 3 filed by new insider Liu Shu
- SEC Form 3 filed by new insider Zhou Mike Yao
- SEC Form 3 filed by new insider Wu Jingyan
- SEC Form 3 filed by new insider Liang Chenyu Andy
- SEC Form EFFECT filed by Cellyan Biotechnology Co. Ltd
- SEC Form F-1 filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
Latest MCK
- SVP, Controller & CAO Rutledge Napoleon B Jr sold $101,612 worth of shares (133 units at $764.00) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 632 units (SEC Form 4)
- EVP, Chief Strategy & BDO Rodgers Thomas L sold $604,420 worth of shares (822 units at $735.30) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 2,268 units (SEC Form 4)
- EVP & Chief HR Officer Smith Leann B sold $1,331,255 worth of shares (1,810 units at $735.50) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 4,798 units (SEC Form 4)
- McKesson Closes Strategic Investment with Apollo Funds for Minority Interest in Medical-Surgical Solutions
- SEC Form 4 filed by EVP & CFO Cheung Kenny K
- SEC Form 3 filed by new insider Cheung Kenny K
- SEC Form SD filed by McKesson Corporation
- EVP and Chief Legal Officer Lau Michele sold $2,701,870 worth of shares (3,550 units at $761.09) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 3,247 units (SEC Form 4)
- EVP & CFO Vitalone Britt J. converted options into 1,476 shares and covered exercise/tax liability with 581 shares, increasing direct ownership by 4% to 21,953 units (SEC Form 4)
- Chief Executive Officer Tyler Brian S. converted options into 4,579 shares and covered exercise/tax liability with 1,831 shares, increasing direct ownership by 11% to 27,774 units (SEC Form 4)